Ratings by H.C. Wainwright (Andrew S. Fein)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/23/2026 | Tscan Therapeutics Inc | TCRX | Maintain | Buy (Buy) |
|
Details | ||
| 6/11/2026 | WAVE Life Sciences | WVE | Maintain | Buy (Buy) |
|
Details | ||
| 6/5/2026 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 5/28/2026 | Catalyst Pharmaceutical Partners | CPRX | Downgrade | Neutral (Buy) |
31.32 (31.42) |
0.32% | Details | |
| 5/21/2026 | PepGen Inc. | PEPG | Maintain | Buy (Buy) |
|
Details | ||
| 5/19/2026 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2026 | Kamada Ltd. | KMDA | Maintain | Buy (Buy) |
|
Details | ||
| 5/12/2026 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 4/14/2026 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2026 | Tscan Therapeutics Inc | TCRX | Maintain | Buy (Buy) |
|
Details | ||
| 3/16/2026 | Savara | SVRA | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2026 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2026 | WAVE Life Sciences | WVE | Maintain | Buy (Buy) |
|
Details | ||
| 2/3/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 12/23/2025 | Savara | SVRA | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2025 | Kamada Ltd. | KMDA | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2025 | PepGen Inc. | PEPG | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2025 | Tscan Therapeutics Inc | TCRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | PepGen Inc. | PEPG | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2025 | PepGen Inc. | PEPG | Maintain | Buy (N/A) |
|
Details | ||
| 9/4/2025 | Savara | SVRA | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2025 | Savara | SVRA | Upgrade | Buy (Neutral) |
3.01 (5.83) |
93.69% | Details | |
| 6/27/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 6/23/2025 | WAVE Life Sciences | WVE | Maintain | Buy (Buy) |
|
Details | ||
| 5/30/2025 | PepGen Inc. | PEPG | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2025 | Savara | SVRA | Downgrade | Neutral (Buy) |
2.13 (3.01) |
41.31% | Details | |
| 5/28/2025 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 5/19/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2025 | WAVE Life Sciences | WVE | Maintain | Buy (Buy) |
|
Details | ||
| 5/9/2025 | PepGen Inc. | PEPG | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2025 | Tscan Therapeutics Inc | TCRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2025 | Acumen Pharmaceuticals, Inc. | ABOS | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2025 | Savara | SVRA | Maintain | Buy (Buy) |
|
Details | ||
| 3/27/2025 | WAVE Life Sciences | WVE | Maintain | Buy (Buy) |
|
Details | ||
| 3/20/2025 | Liquidia Technologies | LQDA | Maintain | Buy (Buy) |
|
Details | ||
| 3/6/2025 | Tscan Therapeutics Inc | TCRX | Maintain | Buy (Buy) |
|
Details | ||
| 3/6/2025 | Kamada Ltd. | KMDA | Maintain | Buy (Buy) |
|
Details | ||
| 3/6/2025 | WAVE Life Sciences | WVE | Maintain | Buy (Buy) |
|
Details | ||
| 1/31/2025 | PepGen Inc. | PEPG | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2024 | Savara | SVRA | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2024 | WAVE Life Sciences | WVE | Maintain | Buy (Buy) |
|
Details | ||
| 10/8/2024 | Savara | SVRA | Maintain | Buy (Buy) |
|
Details | ||
| 10/3/2024 | Acumen Pharmaceuticals, Inc. | ABOS | Maintain | Buy (Buy) |
|
Details | ||
| 10/1/2024 | Savara | SVRA | Maintain | Buy (Buy) |
|
Details | ||
| 9/24/2024 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2024 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2024 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2024 | Liquidia Technologies | LQDA | Maintain | Buy (Buy) |
|
Details | ||
| 6/27/2024 | Savara | SVRA | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2024 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2024 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 7/14/2023 | Theseus Pharmaceuticals Inc. | THRX | Maintain | Buy (N/A) |
|
Details | ||
| 7/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2022 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2022 | PepGen Inc. | PEPG | New Coverage | Buy (N/A) |
14.51 (1.77) |
-87.8% | Details | |
| 6/30/2022 | Theseus Pharmaceuticals Inc. | THRX | New Coverage | Buy (N/A) |
5.20 (4.06) |
-21.92% | Details | |
| 6/30/2022 | Acumen Pharmaceuticals, Inc. | ABOS | New Coverage | Buy (N/A) |
4.88 (2.31) |
-52.66% | Details | |
| 6/21/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 4/11/2022 | Rubius | RUBY | Maintain | Buy (N/A) |
|
Details | ||
| 2/9/2022 | Acadia Pharmaceuticals | ACAD | Upgrade | Buy (N/A) |
25.13 (23.36) |
-7.04% | Details | |
| 2/7/2022 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2022 | Liquidia Technologies | LQDA | Maintain | Buy (N/A) |
|
Details | ||
| 4/7/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Neutral (Buy) |
20.64 (23.36) |
13.18% | Details | |
| 3/15/2021 | Rubius | RUBY | Maintain | Buy (N/A) |
|
Details |
